// App-Quantinova.ai

P914 : EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

Researchers

Presenter

  • Efstathios Kastritis

Principal Investigators

  • Giovanni Palladini

  • Meletios A. Dimopoulos

  • Arnaud Jaccard

  • Giampaolo Merlini

  • Foteini Theodorakakou

  • Despoina Fotiou

  • Monique C. Minnema

  • Ashutosh Wechalekar

  • Stavros Gkolfinopoulos

  • Kyriaki Manousou

  • Pieter Sonneveld

  • Stefan Schnland

Medical Centers

  • Referral Center for AL amyloidosis,Limoge

  • Hematology,Erasmus MC Cancer Institute,Rotterdam,Paesi Bassi

  • Referral Center for AL amyloidosis,Limoge

  • Department of Haematology,University Medical Centre Utrecht, Utrecht University,Utrecht,Paesi Bassi

  • Hematology,Erasmus MC Cancer Institute,Rotterdam,Paesi Bassi

  • Erasmus MC,

  • University Clinic Heidelberg, Heidelberg, Germany

  • Health Data Specialists,Dublin,Ireland

  • Department of Haematology,University Medical Centre Utrecht, Utrecht University,Utrecht,Paesi Bassi

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece

  • Amyloidosis Research and Treatment Center,University of Pavia,Pavia,Italia

  • Health Data Specialists,Dublin,Ирландия

  • Clinical Hematology

  • University Clinic Heidelberg, Heidelberg, Germany

  • Erasmus MC Cancer Center, Rotterdam, Netherlands

  • Amyloidosis Research and Treatment Center,University of Pavia,Pavia,Italia

  • Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands

  • Health Data Specialists,Dublin,Ireland

  • University of Heidelberg,Heidelberg,Германия

  • Department of Clinical Therapeutics, School

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Hematology,Erasmus MC Cancer Institute,Rotterdam,Paesi Bassi

  • Clinical Haematology, Cancer Division,University College London Hospital,London,Royaume-uni

  • Referral Center for AL amyloidosis,Limoge

  • Erasmus MC Institute,Rotterdam,Netherlands

  • University Clinic Heidelberg, Heidelberg, Germany

  • Referral Center for AL amyloidosis,Limoge

  • University Clinic Heidelberg, Heidelberg, Germany

  • Health Data Specialists,Dublin,Ireland

  • Amyloidosis Research and Treatment Center,University of Pavia,Pavia,Italia

  • Referral Center for AL amyloidosis,Limoge

  • Amyloidosis Research and

  • Referral Center for AL amyloidosis,Limoge

  • Department of Haematology,University Medical Centre Utrecht, Utrecht University,Utrecht,Paesi Bassi

  • Clinical Haematology, Cancer Division,University College London Hospital,London,Royaume-uni

  • Amyloidosis Research and Treatment Center,University of Pavia,Pavia,Italia

  • Departme

  • Health Data Specialists,Dublin,Ireland

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Health Data Specialists,Dublin,Ireland

  • Clinical Haematology, Cancer Division,University College London Hospital,London,Royaume-uni

  • University Clinic Heidelberg, Heidelberg, Germany

  • Hematology,Erasmus MC Cancer Institute,Rotterdam,Paesi Bassi

  • Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands

  • University Clinic Heidelberg, Heidelberg, Germany

  • Erasmus MC Cancer Institute,Rotterdam,Нидерланды

  • Clinical Haematology, Cancer Division,University College London Hospital,London,Royaume-uni

Locations

  • United States

  • Italy

  • France

  • Netherlands

  • United Kingdom

  • Ireland

  • South Africa

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • AL Amyloidosis

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

Outcome

  • N/A

Study Design

  • Open Label

  • Multinational

  • Prospective

Phase

  • II

Study Id's

  • NCT04617925

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved